Solute Guard Therapeutics Overview

  • Year Founded
  • 2024

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $197K

  • Investors
  • 3

Solute Guard Therapeutics General Information

Description

Developer of monoclonal antibody therapeutics designed to treat Sjögren's Disease and other chronic inflammatory diseases. The company's lead program focuses on Sjögren's Disease, with additional applications in rheumatoid arthritis and other chronic inflammatory diseases, enabling clinicians to drive inflammatory responses across a wide range of diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 35 Ballards Lane
  • London N3 1XW
  • England, United Kingdom
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 35 Ballards Lane
  • London N3 1XW
  • England, United Kingdom

Solute Guard Therapeutics Timeline

20252026
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Solute Guard Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC 21-Feb-2025 $197K Completed Startup
1. Joint Venture 08-Aug-2024 Completed Startup
To view Solute Guard Therapeutics’s complete valuation and funding history, request access »

Solute Guard Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
A Ordinary
To view Solute Guard Therapeutics’s complete cap table history, request access »

Solute Guard Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Solute Guard Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
AMPLEIA Corporation Minority
BaseLaunch Accelerator/Incubator Majority
NG Bio (UK) Venture Capital Majority
To view Solute Guard Therapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial

Solute Guard Therapeutics FAQs

  • When was Solute Guard Therapeutics founded?

    Solute Guard Therapeutics was founded in 2024.

  • Where is Solute Guard Therapeutics headquartered?

    Solute Guard Therapeutics is headquartered in London, United Kingdom.

  • What is the size of Solute Guard Therapeutics?

    Solute Guard Therapeutics has 4 total employees.

  • What industry is Solute Guard Therapeutics in?

    Solute Guard Therapeutics’s primary industry is Drug Delivery.

  • Is Solute Guard Therapeutics a private or public company?

    Solute Guard Therapeutics is a Private company.

  • What is the current valuation of Solute Guard Therapeutics?

    The current valuation of Solute Guard Therapeutics is .

  • What is Solute Guard Therapeutics’s current revenue?

    The current revenue for Solute Guard Therapeutics is .

  • How much funding has Solute Guard Therapeutics raised over time?

    Solute Guard Therapeutics has raised $197K.

  • Who are Solute Guard Therapeutics’s investors?

    AMPLEIA, BaseLaunch, and NG Bio (UK) have invested in Solute Guard Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process